Navigation Links
TGen and George Mason University announce precision medicine alliance to benefit patients
Date:5/6/2014

PHOENIX, Ariz. and FAIRFAX, Va. May 6, 2014 The Translational Genomics Research Institute (TGen) and George Mason University today announced the creation of a strategic research alliance to benefit patients with cancer and other life-threatening illnesses.

The TGen-George Mason Molecular Medicine Alliance is a groundbreaking effort in precision medicine, which recommends to clinicians the best medications and treatments based on each patient's molecular profile.

Both institutions are world leaders in exploring the underlying fundamentals of disease by studying genes and proteins. By combining efforts, George Mason and TGen look to develop a more precise research strategy to help people afflicted by cancer and other diseases, while pursuing additional research. The alliance is the first of its kind in the field.

TGen, at the heart of Phoenix's Biomedical Campus, is recognized as a pioneer in studying genomics, or DNA, to uncover the underlying molecular causes of disease. Mason, strategically located outside the nation's capital, has one of the world's most advanced labs for studying proteins: the Center for Applied Proteomics and Molecular Medicine.

The alliance already has submitted applications for more than $12 million in research grants for projects that each institution might not have pursued alone, but are now well positioned to accomplish by combining their complimentary expertise.

"This is a timely and exceptionally forward looking research effort between George Mason University and TGen. The Molecular Medicine Alliance is an opportunity for two highly regarded institutions to integrate their complementary knowledge and human resources to help patients by using state-of-the-art technology to advance new therapeutics options," said Dr. Jeffrey Trent, TGen President and Research Director.

"This is a major achievement for science and health care," said Dr. ngel Cabrera, President of Mason. "By joining forces, researchers can understand disease at a more refined level and more people can be helped. This is the level of research that all universities and companies strive to achieve."

Both institutions embrace translational medicine moving new laboratory discoveries as quickly as possible into new treatments for patients. Both institutions pursue precision medicine recommending the best medication based on each patient's molecular profile.

The alliance extends both Mason's and TGen's footholds to the other sides of the nation, expanding each other's network of collaborators and clinical trials, and advancing new treatments to the public.

Using genomics to sort out genetic changes that lead to disease, TGen has conducted extensive clinical trials that have led to new treatments approved by the U.S. Food and Drug Administration (FDA). Using that model, Mason has the opportunity to use proteomics to develop new FDA approved treatments, including finding new uses for already approved FDA drugs.

By integrating genomics and proteomics, the alliance will initially focus on discoveries in four specific areas of research:

  • New treatments for patients with breast cancer or melanoma.
  • Treatments for patients with breast cancer that has spread to the bone and brain.
  • Biomarkers that can help diagnose traumatic injuries, such as brain concussions.
  • Developing a better understanding of infectious diseases and the human immune system, leading to new vaccines.

Through the alliance, Mason and TGen will have the opportunity to develop new discoveries, benefitting patients through new technologies. Mason students will have opportunities to intern at TGen. And the partners hope the alliance will have significant economic impact, creating jobs and new commercial businesses both in Arizona and Virginia.

The alliance will be celebrated at an event Friday, May 9, in the Mason Inn, Junior Ballroom on the Mason campus in Fairfax, Va.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. Georgetown physician leads national resveratrol study for Alzheimers disease
2. James George, MD: 2012 ASH Wallace H. Coulter Award for Lifetime Achievement in Hematology
3. George Mason University researchers target breast cancer in 3 trials
4. Allied Minds and The George Washington University partner to form LuxCath LLC
5. Worldwide Internet Sensation and Ashland Musician George Dennehy Performs at the Science Museum of Virginia
6. Houston Rodeo Tickets: Official Onsales for Bruno Mars, George Strait, Blake Shelton, Luke Bryan, Pitbull, Zac Brown Band, Toby, Keith & Tim McGraw on Sat. Jan. 12th
7. Rushfit Ultimate Home Fitness: Review Examining George St Pierre’s Program Released
8. Georgetown and Temple Oral Surgeon at Austin Oral Surgery Donates to Local School
9. Dental Plus Management LLC, Welcomes Dr. George Daszko to DentalDeal.com
10. The George Washington University will hold symposium on Latino health disparities
11. Hydrotherapy Course Featuring HydroWorx Pool at St. George’s Park National Football Centre
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology: